Wellington Management's $571B Q4 Portfolio: The Stock Picker's Stock Picker Built a $14B Eli Lilly Position While Everyone Else Was Chasing AI

Wellington Management is the quiet giant of institutional investing. Founded in 1928, it's one of the oldest and largest independent investment management firms in the world — and unlike most of its peers in the $500B+ AUM club, it runs no ETFs and no index funds. Every dollar in Wellington's $571 billion 13F filing represents an active investment decision.

That distinction matters enormously when reading its Q4 2025 filing. When Schwab IM adds 0.3% to Microsoft, that's index tracking. When Wellington does it, that's a portfolio manager making a call. And Wellington's calls in Q4 were notably different from the passive consensus.

The Healthcare Tilt Nobody Else Has

Wellington's most distinctive positioning is in healthcare. Two pharma giants sit in the top 10:

• Eli Lilly at $14.4B (2.52%) — the 7th largest holding, up $3.2B QoQ despite shares being trimmed 8.3%
• Merck (MRK) at $9.1B (1.59%) — shares increased 14.8%, a $2.8B value increase

Combined, Lilly and Merck represent $23.5B or 4.1% of the portfolio. Add UnitedHealth ($5.2B) and Johnson & Johnson ($4.8B), and healthcare accounts for over $33B — nearly 6% of total assets. No other mega-filer in our coverage has this kind of healthcare concentration.

The Merck build is particularly telling. While the street has been obsessed with GLP-1 drugs (Lilly) and AI infrastructure (NVIDIA), Wellington's active managers increased their Merck position by 14.8% in shares. Merck's Keytruda cancer franchise generates $25B+ in annual revenue, and the patent cliff concern has pushed the stock to a relatively modest valuation. Wellington appears to be buying the fear.

Meta Trimmed 18% — Active Managers Walk Away

The sharpest divergence from passive consensus: Wellington cut its Meta Platforms position by 18% in shares, reducing it from $7.9B to $5.8B. This goes directly against the index funds, which added Meta as its S&P 500 weight fluctuated.

At Schwab, Meta shares grew 7.8%. At Invesco, Meta shares grew 6.1%. At Bank of America, Meta shares grew with Merrill's model portfolios. Wellington went the other direction — and it's the only pure active manager in this comparison set.

The message: when humans are making stock-by-stock decisions unconstrained by index weights, Meta's Q4 valuation didn't pass muster. Wellington's active managers saw something that the passive machines didn't price in.

Amazon Built 13%, Microsoft Trimmed 5%

Wellington made a notable swap within the mega-cap tech space: cutting Microsoft by 5.2% in shares while building Amazon by 13.2%. The two stocks are the closest comparable pair in the portfolio — both cloud infrastructure leaders with dominant market positions.

The rotation suggests Wellington's managers view Amazon's AWS + retail combination as relatively undervalued versus Microsoft's Azure + enterprise software play. With Microsoft trading at a higher P/E multiple, the active allocation shifted toward what Wellington sees as the better risk-reward.

Broadcom Added, Apple Trimmed — Semiconductor Conviction

Broadcom shares grew 1.6% while Apple shares fell 7.7%. This mirrors the semiconductor-over-hardware thesis we've seen at Capital World Investors, which made Broadcom its #1 holding. Wellington's active managers are choosing the AI infrastructure layer (Broadcom's custom AI chips for hyperscalers) over the consumer hardware layer (Apple's iPhone cycle).

NVIDIA was modestly trimmed (-1.9% shares) but remains the #1 holding at $26.2B. The trim is small enough to be rebalancing rather than conviction change.

The Wells Fargo Position: Betting on Banks

Wellington holds $6.8B in Wells Fargo, making it the 10th largest holding. But shares were trimmed 12.1% in Q4, and the position dropped from $6.9B to $6.8B. The trim came after Wells Fargo's strong Q3-Q4 rally, suggesting profit-taking after the bank exceeded expectations.

The financials allocation is broader than just Wells Fargo: Mastercard sits at $7.7B (#9), growing 9.7% in shares. Wellington's active bet in financials is shifting from traditional banking toward payment networks — higher-margin, less capital-intensive, less regulatory risk.

How Wellington Stands Alone

Among the 8 filers we've profiled this quarter, Wellington is the only pure active manager:

• BofA, Schwab, Invesco: Heavily or partially index-driven
• JPMorgan, Morgan Stanley, Goldman: Mix of wealth management, trading, and proprietary
• Wellington: Every position is an active choice — no index, no ETF, no passive component

This makes Wellington's filing the single most useful signal for understanding what fundamental stock pickers actually believe about Q4 2025. The healthcare overweight, Meta underweight, and Amazon build represent pure alpha-seeking conviction — not index inertia or client-directed allocation.

What Investors Should Watch

• Healthcare conviction growing: Merck +14.8% in shares while cutting Lilly shares 8.3% (but value still rose $3.2B). Wellington is actively managing pharma exposure.
• Meta skepticism: -18% in a quarter when passive funds added. Active managers may see regulatory or capex risks the indices ignore.
• Amazon over Microsoft: A meaningful active rotation between the two cloud leaders — worth monitoring for continuation.
• Mastercard over Wells Fargo: Financials shifting from banks to payments — a high-conviction active bet on margin quality.

Wellington doesn't chase trends. It has survived since 1928 by being right about stocks over long horizons. When the largest pure active manager in the world trims Meta and builds Merck, it's worth paying attention.